Share on StockTwits

MannKind (NASDAQ:MNKD) CFO Matthew J. Pfeffer sold 20,000 shares of the company’s stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $10.44, for a total value of $208,800.00. Following the transaction, the chief financial officer now directly owns 126,784 shares of the company’s stock, valued at approximately $1,323,625. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

MannKind (NASDAQ:MNKD) traded up 1.21% on Thursday, hitting $10.00. The stock had a trading volume of 5,846,291 shares. MannKind has a one year low of $3.80 and a one year high of $11.48. The stock has a 50-day moving average of $9.52 and a 200-day moving average of $6.77. The company’s market cap is $3.779 billion.

MannKind (NASDAQ:MNKD) last released its earnings data on Monday, May 12th. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.13) by $0.01. During the same quarter in the prior year, the company posted ($0.15) earnings per share. Analysts expect that MannKind will post $-0.36 EPS for the current fiscal year.

A number of analysts have recently weighed in on MNKD shares. Analysts at ISI Group downgraded shares of MannKind from a “buy” rating to a “hold” rating in a research note on Tuesday. They now have a $11.00 price target on the stock, up previously from $10.00. Separately, analysts at MLV & Co
downgraded shares of MannKind from a “buy” rating to a “hold” rating in a research note on Tuesday. They now have a $11.00 price target on the stock, up previously from $10.00. They noted that the move was a valuation call. Finally, analysts at Brinson Patrick raised their price target on shares of MannKind from $12.00 to $15.00 in a research note on Monday. They now have an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. MannKind currently has a consensus rating of “Hold” and a consensus price target of $9.56.

MannKind Corporation (NASDAQ:MNKD) is a development-stage biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.